These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32696071)

  • 1. Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer.
    Failing JJ; Aubry MC; Mansfield AS
    Cancer Immunol Immunother; 2021 Jan; 70(1):215-219. PubMed ID: 32696071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer.
    Kikuchi E; Yamazaki K; Torigoe T; Cho Y; Miyamoto M; Oizumi S; Hommura F; Dosaka-Akita H; Nishimura M
    Cancer Sci; 2007 Sep; 98(9):1424-30. PubMed ID: 17645781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.
    Kudo Y; Haymaker C; Zhang J; Reuben A; Duose DY; Fujimoto J; Roy-Chowdhuri S; Solis Soto LM; Dejima H; Parra ER; Mino B; Abraham R; Ikeda N; Vaporcyan A; Gibbons D; Zhang J; Lang FF; Luthra R; Lee JJ; Moran C; Huse JT; Kadara H; Wistuba II
    Ann Oncol; 2019 Sep; 30(9):1521-1530. PubMed ID: 31282941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.
    Molina-Alejandre M; Perea F; Calvo V; Martinez-Toledo C; Nadal E; Sierra-Rodero B; Casarrubios M; Casal-Rubio J; Martinez-Martí A; Insa A; Massuti B; Viteri S; Barneto Aranda I; Rodriguez-Abreu D; de Castro J; Martínez JM; Cobo M; Wistuba II; Parra ER; Martín-López J; Megías D; Muñoz-Viana R; Garrido F; Aptsiauri N; Ruiz-Cabello F; Provencio M; Cruz-Bermúdez A
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39428126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor mutational load, CD8
    Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
    Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?
    Ramnath N; Tan D; Li Q; Hylander BL; Bogner P; Ryes L; Ferrone S
    Cancer Immunol Immunother; 2006 Aug; 55(8):891-9. PubMed ID: 16187081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.
    Perea F; Bernal M; Sánchez-Palencia A; Carretero J; Torres C; Bayarri C; Gómez-Morales M; Garrido F; Ruiz-Cabello F
    Int J Cancer; 2017 Feb; 140(4):888-899. PubMed ID: 27785783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer.
    Hanagiri T; Shigematsu Y; Shinohara S; Takenaka M; Oka S; Chikaishi Y; Nagata Y; Baba T; Uramoto H; So T; Yamada S
    Anticancer Res; 2013 May; 33(5):2123-8. PubMed ID: 23645764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape.
    Song SG; Kim S; Koh J; Yim J; Han B; Kim YA; Jeon YK; Chung DH
    Cancer Immunol Immunother; 2021 Jul; 70(7):2035-2048. PubMed ID: 33420630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.
    Sabbatino F; Liguori L; Polcaro G; Salvato I; Caramori G; Salzano FA; Casolaro V; Stellato C; Col JD; Pepe S
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer.
    Lin A; Zhu CC; Chen HX; Chen BF; Zhang X; Zhang JG; Wang Q; Zhou WJ; Hu W; Yang HH; Xu HH; Yan WH
    J Cell Mol Med; 2010 Sep; 14(9):2318-29. PubMed ID: 19602033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients.
    Baba T; Shiota H; Kuroda K; Shigematsu Y; Ichiki Y; Uramoto H; Hanagiri T; Tanaka F
    Int J Clin Oncol; 2013 Dec; 18(6):997-1004. PubMed ID: 23124547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
    Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
    Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
    Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
    Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer.
    He XP; Song FJ; Liu XY; Wang Z; Li XX; Liu FY; Chen G; Jiang WP
    J Int Med Res; 2013 Oct; 41(5):1473-83. PubMed ID: 23975858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of HLA class I molecules in the immune escape of urologic tumors.
    Carretero R; Gil-Julio H; Vázquez-Alonso F; Garrido F; Castiñeiras J; Cózar JM
    Actas Urol Esp; 2014 Apr; 38(3):192-9. PubMed ID: 24315763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.